ES2381452T3 - PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas - Google Patents

PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas Download PDF

Info

Publication number
ES2381452T3
ES2381452T3 ES08839793T ES08839793T ES2381452T3 ES 2381452 T3 ES2381452 T3 ES 2381452T3 ES 08839793 T ES08839793 T ES 08839793T ES 08839793 T ES08839793 T ES 08839793T ES 2381452 T3 ES2381452 T3 ES 2381452T3
Authority
ES
Spain
Prior art keywords
alkyl
alkylene
aryl
group
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08839793T
Other languages
English (en)
Inventor
Pascale Pouzet
Ralf; DOLLINGER Horst ANDERSKEWITZ
Dennis; FOX Thomas FIEGEN
Rolf; HOENKE Christoph GOEGGEL
Domnic; NICKOLAUS Peter MARTYRES
Klaus Klinder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39154006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2381452(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2381452T3 publication Critical patent/ES2381452T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de fórmula 1, R3 en la cual X es SO o SO2; R1 es H, alquilo C1-6, R2 es H o un radical seleccionado del grupo consistente en alquilo C1-10 y alquenilo C2-6, que eventualmente puede estar sustituido con uno o varios radicales seleccionados de halógeno y fluoroalquilo C1-3 o que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo que consiste en OROR2.1 SR2.1 SO2-R2.1, COOR2.1 , CONR2.2R2.3 , , SO-R2.1 , , arilo C6-10, -Het, Hetarilo, un cicloalquilo C3-10 monocíclico o bicíclico, CH2-NR2.2R2.3 y NR2.2R2.3 , que, de nuevo, puede estar eventualmente sustitudo con uno o varios radicales seleccionados del grupo consistente en OH, halógeno, OR2.1, oxo, CF3, CHF2, CH2F, alquilo C1-6, alcanol C1-6, arilo C6-10, COOR2.1 , CH2-NR2.2R2.3 y NR2.2R2.3 , en donde Het es un heterociclo de uno a once miembros, mono-o bi-cíclico, saturado o parcialmente saturado, eventualmente condensado o eventualmente puenteado, que contiene 1, 2, 3 ó 4 heteroátomos elegidos, independientemente uno de otro, del grupo consistente en N, S u O, y en donde Hetarilo es un heteroarilo de cinco a diez miembros, mono-o bi-cíclico, eventualmente condensado, que contiene 1, 2, 3 ó 4 heteroátomos seleccionados, independientemente uno de otro, del grupo consistente en N, S u O, y en donde cicloalquilo puede estar saturado o parcialmente saturado, en donde R2.1 es H o un radical seleccionado del grupo consistente en alquilo C1-6-, alcanol C1-6, haloalquilo C1-3, cicloalquilo C3-10 mono-o bi-cíclico, aril C6-10-alquileno C1-6, hetaril-alquileno C1-6, Het-alquileno C1-6, cicloalquil C3-10-alquileno C1-6, un arilo C6-10 mono-o bi-cíclico, heteroarilo y un -Het, que eventualmente puede estar sustituido con uno varios radicales seleccionados del grupo consistente en OH, O- (alquilo C1-3) , halógeno, alquilo C1-6 y arilo C6-10, y R2.3 en donde R2.2 son, de modo independiente entre sí, H o un radical que está seleccionado del grupo compuesto por alquilo C1-6, cicloalquilo C3-10 mono-o bicíclico, aril C6-10-alquileno C1-6, hetarilalquileno C1-6, arilo C6-10 mono-o bicíclico, Het, Hetarilo, CO-NH2, CO-NHCH3, CO-N (CH3) 2, SO2 (alquilo C1-C2) , CO-R2.1 y COOR2.1 , que eventualmente puede estar sustituido con uno o más radicales seleccionados del grupo consistente en OH, halógeno, alquilo C1-6, arilo C6-10 y COOR2.1 , o R2 es un cicloalquilo C3-10 mono-o policíclico que eventualmente puede estar puenteado una o varias veces a través de grupos alquilo C1-3 y que eventualmente puede estar sustituido con un radical seleccionado del grupo compuesto por alcanol C1-6 ramificado o no ramificado, fluoroalquilo C1-3, alquilen C1-3-OR2.1, OR2.1 , COOR2.1 , - SO2-NR2.2R2.3, Het, -NH-CO-O- (alquilo C1-6) , -NH-CO- (alquilo C1-6) , -NH-CO-O- (arilo C6-10) , -NH-CO- (arilo C6-10) , -NH-CO-O-Hetarilo, -NH-CO-Hetarilo, -NH-CO-O- (alquilen C1-3) - (arilo C6-10) , -NH-CO- (alquilen C1-3) (arilo C6-10) , -N (alquil C1-3) -CO- (alquilo C1-6) , -N (alquil C1-3) -CO-O- (arilo C6-10) , -N (alquil C1-3) -CO- (arilo C6-10) , - N (alquil C1-3) -CO-O-Hetarilo, -N (alquil C1-3) -CO-hetarilo, -N (alquil C1-3) -CO-O- (alquilen C1-3) - (arilo C6-10) , N (alquil C1-3) -CO- (alquilen C1-3) - (arilo C6-10) , arilo C6-10, alquilo C1-6, aril C6-10-alquileno C1-6, Hetaril-alquileno C1-6, cicloalquilo C3-10 mono-o bi-cíclcico y NR2.2R2.3 , que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo compuesto por OH, OR2.1, oxo, halógeno, CF3, CHF2, CH2F, alquilo C1-6, arilo C6-10 y NR2.2R2.3 , o R2 es un arilo C6-10 mono-o poli-cíclico, que eventualmente puede estar sustituido con OH, SH o halógeno o OR2.1 NR2.2R2.3 con uno o varios radicales seleccionados del grupo consistente en , COOR2.1 , , CH2NR2.2R2.3, cicloalquilo C3-10, Het, alquilo C1-6, fluoroalquilo C1-3, CF3, CHF2, CH2F, aril C6-10-alquileno C1-6, Het-alquileno C1-6, Hetaril-alquileno C1-6, arilo C6-10, SO2-CH3, SO2-CH2CH3 y SO2-NR2.2R2.3 , que, de nuevo, puede estar eventualmente sustituido con uno o varios radicales seleccionados del grupo consistente en OH, OR2.1, CF3, CHF2, CH2F, oxo, halógeno, CF3, CHF2, CH2F, alquilo C1-6, arilo C6-10 y NR2.2R2.3 , o R2 es un radical seleccionado de un grupo consistente en Het y Hetarilo, que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo halógeno, OH, oxo, CF3, CHF2 y CH2F o con uno o varios radicales seleccionados del grupo OR2.1, alquilen C1-3-OR2.1, SR2.1, SO-R2.1, SO2-R2.1, COOR2.1 , COR2.1, alcanol C1-6, cicloalqulo C3-10 mono-o bi-cíclico, arilo C6-10, alquilo C1-6, aril C6-10-alquileno C1-6, hetaril-alquileno C1-6, Het, Hetarilo, alquilen C1-3-OR2.1 y NR2.2R2.3 , que, de nuevo, eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo compuesto por OH, OR 2.1, oxo, halógeno, CF3, CHF2, CH2F, alquilo C1-6, arilo C6-10 y NR2.2R2.3 , o en donde NR1R2 son juntos un anillo heterocíclico C4-7 que eventualmente puede estar puentado, que contiene 1, 2 ó 3 heteroátomos seleccionados del grupo consistente en N, O y S y que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo consistente en OH, OR2.1, alquilen C1-3-OR.1 , oxo, halógeno, alquilo C1-6, arilo C6-10, COOR2.1, CH2-NR2.2-COO-R2.1, CH2-NR2.2-CO-R2.1, CH2-NR2.2-CO-CH2 NR2.2R2.3 CH2-NR2.2-SO2-NR2.2R2.3 , CH2-NR2.2-SO2-alquilo C1-3, , CH2-NR2.2-CO-NR2.2R2.3 , CO-NR2.2R2.3 , CH2-NR2.2R2.3 y NR2.2R2.3 , y en donde R3 es un arilo C6-10, que, eventualmente, puede estar sustituido en posición orto, para o meta con uno, dos o tres radicales seleccionados, independientemente uno de otro, del grupo consistente en flúor, cloro, bromo, hidroxi, CN, alquilo C1-6, fluoroalquilo C1-3, -alquilen C1-3-OR2.1, -alquilen C1-3-NR2.2R2.3, -NR2.2R2.3, O-R2.1; SO-R2.1, SO2R2.1, COOR2.1 , -CO-NH- (alquilen C1-6) -Hetarilo, -CO-NH-Hetarilo, -CO-N (CH3) -Het, -CO-N (CH3) - (alquilen C1-3) -Het, -CO-N (CH3) - (alquilen C1-3) -Hetarilo, -CO-N (cicloalquil C3-7) -Het, -CO-NR2.2R2.3 , -CO-NH (alquilen C1-6) -Het, NR2.2-CO-R2.1, arilo C6-10, aril C6-10-alquileno C1-2, Het-alquileno C1-2, -Het, -CO-Het, CO-N (CH3) -cicloalquilo C3-7, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-2, Hetaril-alquileno C1-2 y Hetarilo, en donde este radical puede estar eventualmente sustituido con uno o varios radicales seleccionados del grupo consistente en OH, halógeno, -fluoroalquilo C1-3, oxo, metilo y fenilo, o en donde R3 es un radical seleccionado del grupo consistente en Het y Hetarilo, que eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo consistente en halógeno, fluoroalquilo C1-3, CN, OH, oxo, -alquilo C1-6, -alquilen C1-3-NR2.2R2.3 , -NR2.2R2.3, SO-R2.1, SO2-R2.1, -O-R2.1 , -COOR2.1, SO2 (CH3) , SO2- (CH2-CH3) , arilo C6-10, Het, cicloalquilo C3-7 y Hetarilo, que, de nuevo, eventualmente puede estar sustituido con uno o varios radicales seleccionados del grupo consistente en OH, halógeno, -fluoroalquilo C1-3, alquilo C1-6, arilo C6-10, -COO (alquilo C1-3) y O- (alquilo C1-3) , o en donde R3 es -O-R3.1 , en donde R3.1 es un radical seleccionado del grupo consistente en -alquilo C1-6, -arilo C6-10, -alquilen C1-3-arilo C6-10, Hetarilo y Het, que, eventualmente puede estar sustituido, en posición orto, para o meta, con uno, dos o tres radicales seleccionados, independientemente uno de otro, del grupo consistente en flúor, cloro, bromo, hidroxi, CN, alquilo C1-6, fluoroalquilo C1-3, CO- (alquilo C1-5) , -CO- (fluoroalquilo C1-3) , -CONH- (alquilen C1-6) -Hetarilo, -CO-N (alquil C1-3) - (alquilen C1-6) -Hetarilo, -CO-N (alquil C1-3) -Het, -CO-N (cicloalquil C3-7) -Het, -alquilen C1-3-OR2.1 , -alquilen C1-3-NR2.2R2.3, -NR2.2R2.3, O-R2.1; SO-R2.1, SO2-R2.1, COOH, COO- (alquilo C1-4) , -O-alquilen C1-3-N (alquilo C1-3) 2, CO-NR2.2R2.3, NR2.2-CO-R2.1 , arilo C6-10, aril C6-10-alquileno C1-2, Het-alquileno C1-2, -CO-Het, Het, -CO-cicloalquilo C3-7, -CO-N (alquil C1-3) -cicloalquilo C3-7, ciloalquilo C3-7, ciloalquil C3-7-alquileno C1-2, Hetaril-alquileno C1-2 y Hetarilo, que, de nuevo, eventualmente puede estar sustituido con 1, 2, 3 ó 4 radicales seleccionados, independientemente uno de otro, del grupo consistente en F, Cl, Br, metilo, O-metilo, etilo, O-etilo, OH, oxo y CF3. y en donde R4 es H, CN, OH, CF3, CHF2, CH2F, F, metilo, etilo, -O- (alquilo C1-3) , -alquilen C1-3-OH, -COO (alquilo C1-3) , -CO-Het, - (alquilen C1-2) -NH-SO2- (alquilo C1-2) , - (alquilen C1-2) -N (alquil C1-3) -SO2- (alquilo C1-2) , - (alquilen C1-2) -O- (alquilen C1-2) -arilo C6-10, -alquilen C1-3-O-alquilo C1-3, - (alquilen C1-2) -N (alquil C1-3) -CO- (alquilo C1-2) , -NH-CO- (alquilen C1-3) -O- (alquilo C1-3) , -alquilen C1-3-NH-CO- (alquilo C1-3) , -alquilen C1-3-NH-CO- (alquilen C1-3) -N (alquilo C1-3) 2, -O- (alquilen C1-2) - (arilo C6-10) , -alquilen C1-3-NH-CO- (alquilen C1-3) -O- (alquilo C1-3) , -CO- (arilo C6-10) , - (alquilen C1-2) -N (alquil C1-3) -CO- (alquilen C1-2) -O- (alquilo C1-3) , en donde el arilo en los radicales anteriores puede estar sustituido, eventualmente de nuevo, con uno o varios otros radicales seleccionados del grupo F, Cl, Br, metilo, etilo, propilo, isopropilo, ciclopropilo, -Ometilo, -O-etilo, -O-propilo, -O-isopropilo, -O-ciclopropilo, -OH y CF3 , o en donde R3 y R4 , en común, forman un heterociclo mono-o bi-cíclico insaturado, saturado o parcialmente saturado, que contiene 1, 2 ó 3 heteroátomos seleccionados del grupo consistente en N, O y S y que, eventualmente, puede estar sustituido con uno o varios radicales seleccionados del grupo consistente en halógeno, OH, oxo, fluoroalquilo C1-3, CN, alquilo C1-6, -O-R2.1 , -COOR2.1, SO-R2.1, SO2-R2.1, -alquilen C1-3-NR2.2R2.3 , NR2.2R2.3, arilo C6-10, cicloalquilo C3-7, Het y Hetarilo, así como sales farmacológicamente compatibles de los mismos.
ES08839793T 2007-10-19 2008-10-16 PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas Active ES2381452T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07118901 2007-10-19
EP07118901 2007-10-19
PCT/EP2008/063999 WO2009050248A1 (de) 2007-10-19 2008-10-16 Substituierte piperidino-dihydrothienopyrimidine

Publications (1)

Publication Number Publication Date
ES2381452T3 true ES2381452T3 (es) 2012-05-28

Family

ID=39154006

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13154790.3T Active ES2524910T3 (es) 2007-10-19 2008-10-16 Piperidino-dihidrotienopirimidinas sustituidas
ES08839793T Active ES2381452T3 (es) 2007-10-19 2008-10-16 PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES13154790.3T Active ES2524910T3 (es) 2007-10-19 2008-10-16 Piperidino-dihidrotienopirimidinas sustituidas

Country Status (33)

Country Link
US (1) US8754073B2 (es)
EP (3) EP2215092B1 (es)
JP (2) JP5150728B2 (es)
KR (1) KR101548975B1 (es)
CN (2) CN101827852B (es)
AR (1) AR069075A1 (es)
AT (1) ATE542825T1 (es)
AU (1) AU2008313660B2 (es)
BR (1) BRPI0818006B8 (es)
CA (1) CA2705414C (es)
CL (1) CL2008003096A1 (es)
CY (2) CY1112703T1 (es)
DK (2) DK2610258T3 (es)
EA (1) EA019480B1 (es)
EC (1) ECSP10010156A (es)
ES (2) ES2524910T3 (es)
HR (2) HRP20120334T1 (es)
MA (1) MA31845B1 (es)
ME (1) ME01330B (es)
MX (1) MX2010004026A (es)
MY (1) MY153979A (es)
NZ (1) NZ585346A (es)
PE (2) PE20131463A1 (es)
PL (2) PL2610258T3 (es)
PT (2) PT2610258E (es)
RS (1) RS52271B (es)
SI (2) SI2610258T1 (es)
TN (1) TN2010000175A1 (es)
TW (1) TWI421077B (es)
UA (1) UA99309C2 (es)
UY (1) UY31405A1 (es)
WO (1) WO2009050248A1 (es)
ZA (1) ZA201001683B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
US8653282B2 (en) 2007-10-18 2014-02-18 Boehringer Ingelheim International Gmbh Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein
WO2009050236A1 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Neue piperazino-dihydrothienopyrimidin-derivate
EP2205609B1 (de) 2007-10-19 2017-03-29 Boehringer Ingelheim International GmbH Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
AU2008313660B2 (en) 2007-10-19 2013-11-07 Boehringer Ingelheim International Gmbh Substituted piperidino-dihydrothienopyrimidines
US9161927B2 (en) 2009-02-27 2015-10-20 Boehringer Ingelheim International Gmbh Drug combinations containing PDE4 inhibitors and NSAIDs
EP2555773A1 (de) 2010-04-08 2013-02-13 Boehringer Ingelheim International GmbH Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
WO2011124525A1 (de) 2010-04-08 2011-10-13 Boehringer Ingelheim International Gmbh Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US20130059866A1 (en) * 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US9013997B2 (en) * 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
US9422267B2 (en) 2012-12-26 2016-08-23 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
ES2637716T3 (es) * 2013-02-04 2017-10-16 Grünenthal GmbH Nuevos compuestos de pirimidina condensados sustituidos
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
CN104892720B (zh) * 2014-03-07 2016-10-26 华东师范大学 4,4-二甲基石胆酸-2,3-骈n-芳基吡唑衍生物及其制备方法和应用
WO2018003962A1 (ja) * 2016-06-30 2018-01-04 国立研究開発法人理化学研究所 新規化合物又はその薬理学的に許容される塩
WO2019057806A1 (en) 2017-09-20 2019-03-28 Leo Pharma A/S SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
ES3041129T3 (en) 2017-10-23 2025-11-07 Boehringer Ingelheim Int New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
EP3724195B1 (en) 2017-12-15 2023-12-27 UNION therapeutics A/S Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
PT3724196T (pt) 2017-12-15 2023-01-13 Union Therapeutics As Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase
ES2968822T3 (es) 2017-12-15 2024-05-14 Union Therapeutics As Azetidina dihidrotienopirimidinas sustituidas y su uso como inhibidores de la fosfodiesterasa
WO2020048827A1 (en) * 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
FI4426307T3 (fi) 2021-12-09 2025-09-10 Boehringer Ingelheim Int Uusi suun kautta otettava farmaseuttinen koostumus ja annosteluohjelma progressiivisen interstitiaalisen keuhkosairauden hoitoon
EP4520394A3 (en) 2021-12-09 2025-04-02 Boehringer Ingelheim International GmbH New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
TW202402289A (zh) * 2022-06-02 2024-01-16 大陸商西藏海思科製藥有限公司 Pde4b抑制劑及其用途
TW202408518A (zh) * 2022-06-16 2024-03-01 大陸商武漢人福創新藥物研發中心有限公司 Pde4b抑制劑
CN115040503B (zh) * 2022-07-26 2023-10-10 云南民族大学 螺环二烯酮型木脂素类化合物在制药中的应用
EP4570804A1 (en) * 2022-08-09 2025-06-18 Xizang Haisco Pharmaceutical Co., Ltd. Pde4b inhibitor and use thereof
CN119947728A (zh) 2022-09-28 2025-05-06 勃林格殷格翰国际有限公司 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途
US20260008788A1 (en) 2022-09-29 2026-01-08 Suzhou Ark Biopharmaceutical Co., Ltd. Aza-fused ring compound, preparation method therefor, and use thereof in medicine
JP2026510292A (ja) * 2023-02-28 2026-04-02 上海翊石医薬科技有限公司 ジヒドロチエノピリミジン誘導体の製造方法および使用
CN121127461A (zh) * 2023-04-03 2025-12-12 上海壹迪生物技术有限公司 二氢噻吩并嘧啶类化合物、其制备方法和应用
CN120752243A (zh) * 2023-04-13 2025-10-03 上海壹迪生物技术有限公司 取代的二氢噻吩并嘧啶类化合物、其制备方法和应用
CN116925099B (zh) * 2023-07-21 2025-06-03 厦门大学 手性二氢噻吩并嘧啶亚砜的制备方法及其应用与其2、4位取代化合物
WO2025038987A2 (en) * 2023-08-17 2025-02-20 Katalytic Therapeutics, Inc. Pde4 protein degraders, pharmaceutical compositions, and therapeutic applications
CN121889398A (zh) * 2023-09-25 2026-04-17 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物及其制备方法和用途
CN120398908A (zh) * 2024-02-01 2025-08-01 艾派克斯生物科技有限公司 Pde4b抑制剂及其药物组合物和用途
WO2025162431A1 (zh) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 一种pde4b抑制剂化合物的口服药物组合物及其制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470336A1 (de) * 1962-07-04 1969-03-20 Thomae Gmbh Dr K Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL122810C (es) 1963-06-17
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
NL123139C (es) 1965-03-31
DE2032687A1 (en) 1970-07-02 1972-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
DE1940572A1 (de) 1969-08-08 1971-02-11 Thomae Gmbh Dr K Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
FR2082496A5 (es) 1970-03-18 1971-12-10 Westinghouse Freins & Signaux
DE2121950A1 (en) 1971-05-04 1972-11-23 Dr. Karl Thomae Gmbh, 7950 Biberach Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
DE2750288A1 (de) * 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en) * 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US5187168A (en) * 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
US5491201A (en) 1992-02-06 1996-02-13 The Dow Chemical Company Mesogenic cyclic imino ether-containing compositions and polymerization products thereof
JPH07330777A (ja) 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
JPH09301958A (ja) 1996-05-09 1997-11-25 Nippon Shoji Kk 新規ピリミジン化合物及び抗ロタウイルス剤
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
JP2003520042A (ja) 2000-01-24 2003-07-02 アイシス・ファーマシューティカルス・インコーポレーテッド 誘導性一酸化窒素シンターゼ発現のアンチセンスモジュレーション
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
CN100519558C (zh) 2000-10-12 2009-07-29 贝林格尔英格海姆法玛两合公司 结晶单水合物、其制备方法及其在制备药物组合中的用途
DE10064994A1 (de) * 2000-12-23 2002-07-04 Merck Patent Gmbh Sulfamidothienopyrimidine
US6849638B2 (en) 2001-04-30 2005-02-01 Bayer Pharmaceuticals Corporation 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions
AR035700A1 (es) 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
CZ302786B6 (cs) 2001-06-22 2011-11-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Krystalický bezvodý tiotropiumbromid, zpusob jeho výroby a jeho použití pro výrobu léciva pro lécbu asthmatu
US6587548B2 (en) * 2001-07-17 2003-07-01 Hewlett-Packard Development Co., L.P. Method and system of using a single telephone number for multiple services
WO2003055890A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
DE60320933D1 (de) 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
SE0203304D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
US20050084878A1 (en) 2003-05-16 2005-04-21 Wisconsin Alumni Research Foundation Method for isolating and cloning high molecular weight polynucleotide molecules from the environment
JP2005003345A (ja) 2003-05-21 2005-01-06 Showa Denko Kk 換気兼熱交換装置および空調システム
KR20140119198A (ko) * 2003-10-02 2014-10-08 디에스엠 아이피 어셋츠 비.브이. 변형량의 염소 및 칼륨을 사용하는 미세조류 중에 고농도 디에치에이의 생산
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
JP4740152B2 (ja) 2003-12-23 2011-08-03 セロドス アクスイェ セルスカブ 末梢性５−ｈｔ受容体の修飾因子
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
JP2008540486A (ja) 2005-05-11 2008-11-20 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビター及びテトラヒドロビオプテリン誘導体との組合せ物
MX2007012313A (es) * 2006-04-19 2007-11-21 Boehringer Ingelheim Int Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias.
EP1847543A1 (de) * 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
EA015821B1 (ru) * 2007-04-20 2011-12-30 Глэксо Груп Лимитед Трициклические азотсодержащие соединения в качестве антибактериальных агентов
US8653282B2 (en) 2007-10-18 2014-02-18 Boehringer Ingelheim International Gmbh Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
EP2205609B1 (de) 2007-10-19 2017-03-29 Boehringer Ingelheim International GmbH Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
US20110028441A1 (en) * 2007-10-19 2011-02-03 Boehringer Ingelheim International Gmbh Novel phenyl-substituted piperazino-dihydrothienopyrimidines
AR068888A1 (es) 2007-10-19 2009-12-16 Schering Corp Derivados de 1, 3, 4 - tiadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la quinesina ksp.
WO2009050236A1 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Neue piperazino-dihydrothienopyrimidin-derivate
PE20090875A1 (es) * 2007-10-19 2009-08-08 Astrazeneca Ab Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos
AU2008313660B2 (en) 2007-10-19 2013-11-07 Boehringer Ingelheim International Gmbh Substituted piperidino-dihydrothienopyrimidines
US9161927B2 (en) * 2009-02-27 2015-10-20 Boehringer Ingelheim International Gmbh Drug combinations containing PDE4 inhibitors and NSAIDs
CA2753597A1 (en) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4-inhibitors and nsaids
US20130059866A1 (en) * 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma

Also Published As

Publication number Publication date
EA201000609A1 (ru) 2010-10-29
US8754073B2 (en) 2014-06-17
DK2610258T3 (da) 2014-11-10
TW200918074A (en) 2009-05-01
PT2215092E (pt) 2012-04-10
BRPI0818006B8 (pt) 2021-05-25
CY1112703T1 (el) 2016-02-10
MX2010004026A (es) 2010-04-30
RS52271B (sr) 2012-10-31
HRP20120334T1 (hr) 2012-05-31
AU2008313660A1 (en) 2009-04-23
JP2011500640A (ja) 2011-01-06
HK1145677A1 (en) 2011-04-29
AU2008313660B2 (en) 2013-11-07
MY153979A (en) 2015-04-30
ECSP10010156A (es) 2010-06-29
BRPI0818006B1 (pt) 2019-10-22
UA99309C2 (ru) 2012-08-10
CY1115858T1 (el) 2017-01-25
HRP20141153T1 (hr) 2015-02-13
EP2380891B1 (de) 2013-12-11
DK2215092T3 (da) 2012-05-07
MA31845B1 (fr) 2010-11-01
TN2010000175A1 (fr) 2011-11-11
PL2215092T3 (pl) 2012-07-31
CN101827852B (zh) 2014-07-30
BRPI0818006A2 (pt) 2015-12-22
CA2705414A1 (en) 2009-04-23
PE20131463A1 (es) 2013-12-23
SI2215092T1 (sl) 2012-04-30
CN104069112A (zh) 2014-10-01
CL2008003096A1 (es) 2010-02-12
ATE542825T1 (de) 2012-02-15
KR101548975B1 (ko) 2015-09-01
NZ585346A (en) 2011-09-30
US20110021501A1 (en) 2011-01-27
JP5150728B2 (ja) 2013-02-27
ME01330B (me) 2013-12-20
EP2610258A1 (de) 2013-07-03
EP2215092A1 (de) 2010-08-11
JP5615889B2 (ja) 2014-10-29
PE20091386A1 (es) 2009-10-17
UY31405A1 (es) 2009-05-29
ZA201001683B (en) 2010-10-27
EP2610258B1 (de) 2014-08-27
EP2215092B1 (de) 2012-01-25
SI2610258T1 (sl) 2014-12-31
EA019480B1 (ru) 2014-04-30
WO2009050248A1 (de) 2009-04-23
PL2610258T3 (pl) 2015-02-27
KR20100100807A (ko) 2010-09-15
JP2013064001A (ja) 2013-04-11
CN101827852A (zh) 2010-09-08
AR069075A1 (es) 2009-12-30
TWI421077B (zh) 2014-01-01
EP2380891A1 (de) 2011-10-26
PT2610258E (pt) 2014-10-24
CA2705414C (en) 2016-05-24
ES2524910T3 (es) 2014-12-15

Similar Documents

Publication Publication Date Title
ES2381452T3 (es) PIPERIDINO-DIHIDROTIENOPIRIMIDINAS sustituidas
AR060266A1 (es) Tiazolil - dihidro - indazoles
AR082891A1 (es) Di-azetidinil diamidas como inhibidores de monoacilglicerol lipasas
AR075594A1 (es) Derivados de ( 2-tienil)-sulfonil-amino-1h-indazol como antagonistas de ccr4
PE20221027A1 (es) Nuevos inhibidores de braf como rompedores de la paradoja
PE20150350A1 (es) Acidos 5-aminotetrahidroquinolin-2-carboxilicos novedosos y su uso
AR051921A1 (es) Acidos sustituidos utiles como compuestos farmaceuticos para tratar trastornos respiratorios, composiciones farmaceuticas que los contienen, y procesos para su preparacion
AR074231A1 (es) Derivados de 6, 7, 8, 9-tetrahidro-5h-1, 4, 7, 10a-tetraaza-ciclohept[f]indeno, composiciones farmacéuticas que contienen estos compuestos, su uso en el agonismo del receptor 5-ht2c y procesos para prepararlos.
AR063637A1 (es) Inhibidores de las quinasas y metodos para su utilizacion
AR078535A1 (es) Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras
AR075789A1 (es) Derivados de bencimidazol, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de la prostaglandina microsomica e2 sintasa-1 (mpnges-1)
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
AR083542A1 (es) Piperidin-4-il-azetidin diamidas como inhibidores de monoacilglicerol lipasa
AR091858A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
AR092742A1 (es) Piridinonas antifibroticas
AR086837A1 (es) Moduladores heterociclicos de sintesis lipidica
AR073677A1 (es) Derivados ciclicos de benzimidazol activadores de proteinquinasas de amp, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de diabetes tipo ii, obesidad y otras enfermedades.
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR066171A1 (es) Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer.
AR069077A1 (es) Preparacion de dihidrotienopirimidinas e intermedios usados en la misma
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
PE20161239A1 (es) Compuesto de ciclopenteno y ciclopentadieno para controlar plagas de invertebrados
AR107398A1 (es) Compuestos de 2-oxindol
AR074916A1 (es) Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparacion, composiciones farmaceuticas y su uso en enfermedades cardiovasculares.
AR081182A1 (es) Heterobiaril-ciclohexil-tetraazabenzo[e]azulenos